Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: Analysis of 5840 patients treated at a single institution

Annals of Surgery

Volumn 260, Issue 1, 2014, Pages 149-157

  Van Der Ploeg, Augustinus P T ^a   Haydu, Lauren E ^a,b   Spillane, Andrew J ^a,b   Quinn, Michael J ^a,b   Saw, Robyn Pm ^a,b   Shannon, Kerwin F ^a,b   Stretch, Jonathan R ^a,b   Uren, Roger F ^a,b,c   Scolyer, Richard A ^a,b   Thompson, John F ^a,b,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

melanoma; sentinel node biopsy; wide excision

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; TUMOR VOLUME; UNIVARIATE ANALYSIS; WIDE EXCISION;

DERMATOLOGIC SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84902291091     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000500     Document Type: Article

References (38)

1. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
2. Ross MI, Thompson JF, Gershenwald JE. Sentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversary. Surg Oncol Clin N Am. 2011;20:57-78.
3. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical PracticeGuideline. J Clin Oncol. 2012;23:2912-2918.
4. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. Ann Surg Oncol. 2012;19:3313-3324.
5. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
6. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
7. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452-2459.
8. Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med. 2011;364:1738-1745.
9. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel node biopsy and immediate lymphadenectomy for occult metastases versus nodal observation and delayed lymphadenectomy for nodal recurrence: fourth interim analysis of MSLT-I. Ann Surg Oncol. 2010;17:S22.
10. Nieweg OE. False-negative sentinel node biopsy. Ann Surg Oncol. 2009;16:2089-2091.
11. Thompson JF. The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. Ann Surg Oncol. 2001;8:44S-47S.
12. Mohrle M, Schippert W, Rassner G, et al. Is sentinel lymph node biopsy of therapeutic relevance for melanoma? Dermatology. 2004;209:5-13.
13. Gutzmer R,AlGhazal M, Geerlings H, et al. Sentinel node biopsy inmelanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol. 2005;153:1137-1141.
14. Starz H, Balda BR. Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of 148 patients. Int J Cancer. 2007;121:689-693.
15. Koskivuo I, Talve L, Vihinen P, et al. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Ann Surg Oncol. 2007;14:3566-3574.
16. Leiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol. 2010;17: 129-137.
17. Satzger I, Meier A, Hoy L, et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol. 2011;18:514-520.
18. Morton DL,Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg. 2003;238:538-549; discussion 549-550.
19. Kretschmer L, Hilgers R, Mohrle M, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer. 2004;40:212-218.
20. van Akkooi AC, Bouwhuis MG, de Wilt JH, et al. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. Br J Surg. 2007;94:1293-1299.
21. Nowecki ZI, Rutkowski P, Michej W. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol. 2008;15:2223-2234.
22. Pasquali S, Mocellin S, Campana LG, et al. Early (sentinel lymph node biopsyguided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases : personal experience and literature meta-analysis. Cancer. 2010;116:1201-1209.
23. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington; 2008.
24. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. J Clin Oncol. 2012;30:2912- 2918.
25. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-Update 2012. Eur J Cancer. 2012;48:2375-2390.
26. National Health and Medical Research Council. Clinical Practice Guidelines: The Management of Cutaneous Melanoma. Canberra, Australia: Australian Cancer Network; 1999.
27. Verwer N, Scolyer RA, Uren RF, et al. Treatment and prognostic significance of positive interval sentinel nodes in patients with primary cutaneous melanoma. Ann Surg Oncol. 2011;18:3292-9329.
28. Scolyer RA,Murali R,McCarthy SW, et al. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diag Pathol. 2008;25:100-111
29. Thompson JF, Shaw HM. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome? Ann Surg Oncol. 2002;9: 719-722
30. TestoriA,De Salvo GL,Montesco MC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009;16:2018-2027
31. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol. 2006;24:4464-4471
32. Karim RZ, Scolyer RA, LiW, et al. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg. 2008;247:1003-1010
33. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634
34. van der Ploeg AP, van Akkooi AC, Schmitz PI, et al. EORTCMelanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. Eur J Cancer. 2010;46:2414-2421.
35. van Akkooi AC, Voit CA, Verhoef C, et al. New developments in sentinel node staging in melanoma: controversies and alternatives. Curr Opin Oncol. 2010;22:169-177.
36. van Akkooi ACJ, Nowecki Z, Voit C, et al. Minimal sentinel node (SN) tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival inmelanoma patients.Amulticenter study in 388 SNpositive patients. Ann Surg. 2008;248:949-955.
37. van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol. 2011;29:2206-2214
38. Morton DL, Cochran AJ, Thompson JF. Sentinel-node biopsy in melanoma. N Engl J Med. 2007;356:419-420